Enlivex Therapeutics’ (ENLV) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Enlivex Therapeutics (NASDAQ:ENLV) in a research report sent to investors on Monday morning,Benzinga reports. D. Boral Capital currently has a $13.00 price objective on the stock.

Separately, HC Wainwright lifted their target price on shares of Enlivex Therapeutics from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, March 24th.

Enlivex Therapeutics Stock Up 3.4 %

Shares of ENLV opened at $0.92 on Monday. The stock has a market cap of $19.69 million, a P/E ratio of -0.94 and a beta of 0.85. The business’s 50 day moving average price is $1.01 and its 200-day moving average price is $1.15. Enlivex Therapeutics has a 52 week low of $0.81 and a 52 week high of $1.84.

Enlivex Therapeutics (NASDAQ:ENLV) last released its earnings results on Monday, March 31st. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.07). On average, equities analysts anticipate that Enlivex Therapeutics will post -0.7 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Millennium Management LLC purchased a new stake in Enlivex Therapeutics in the fourth quarter worth approximately $742,000. Renaissance Technologies LLC grew its holdings in shares of Enlivex Therapeutics by 112.6% in the fourth quarter. Renaissance Technologies LLC now owns 158,992 shares of the company’s stock worth $186,000 after acquiring an additional 84,203 shares during the period. Finally, Two Sigma Securities LLC purchased a new stake in Enlivex Therapeutics during the fourth quarter valued at $26,000. 1.02% of the stock is owned by hedge funds and other institutional investors.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.